129 related articles for article (PubMed ID: 18303217)
1. Unrelated bone marrow transplantation with a reduced toxicity myeloablative conditioning regimen in Wiskott-Aldrich syndrome.
Kang HJ; Shin HY; Ko SH; Park JA; Kim EK; Rhim JW; Kim JG; Ahn HS
J Korean Med Sci; 2008 Feb; 23(1):146-8. PubMed ID: 18303217
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M;
Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656
[TBL] [Abstract][Full Text] [Related]
3. Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report.
Burroughs LM; Petrovic A; Brazauskas R; Liu X; Griffith LM; Ochs HD; Bleesing JJ; Edwards S; Dvorak CC; Chaudhury S; Prockop SE; Quinones R; Goldman FD; Quigg TC; Chandrakasan S; Smith AR; Parikh S; Dávila Saldaña BJ; Thakar MS; Phelan R; Shenoy S; Forbes LR; Martinez C; Chellapandian D; Shereck E; Miller HK; Kapoor N; Barnum JL; Chong H; Shyr DC; Chen K; Abu-Arja R; Shah AJ; Weinacht KG; Moore TB; Joshi A; DeSantes KB; Gillio AP; Cuvelier GDE; Keller MD; Rozmus J; Torgerson T; Pulsipher MA; Haddad E; Sullivan KE; Logan BR; Kohn DB; Puck JM; Notarangelo LD; Pai SY; Rawlings DJ; Cowan MJ
Blood; 2020 Jun; 135(23):2094-2105. PubMed ID: 32268350
[TBL] [Abstract][Full Text] [Related]
4. Unrelated donor BMT for Wiskott-Aldrich syndrome.
Lenarsky C; Weinberg K; Kohn DB; Parkman R
Bone Marrow Transplant; 1993 Aug; 12(2):145-7. PubMed ID: 8401361
[TBL] [Abstract][Full Text] [Related]
5. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.
Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H
Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
8. Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study.
Kang HJ; Shin HY; Park JE; Chung NG; Cho B; Kim HK; Kim SY; Lee YH; Lim YT; Yoo KH; Sung KW; Koo HH; Im HJ; Seo JJ; Park SK; Ahn HS;
Biol Blood Marrow Transplant; 2010 Nov; 16(11):1582-8. PubMed ID: 20685256
[TBL] [Abstract][Full Text] [Related]
9. A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome.
Shekhovtsova Z; Bonfim C; Ruggeri A; Nichele S; Page K; AlSeraihy A; Barriga F; de Toledo Codina JS; Veys P; Boelens JJ; Mellgren K; Bittencourt H; O'Brien T; Shaw PJ; Chybicka A; Volt F; Giannotti F; Gluckman E; Kurtzberg J; Gennery AR; Rocha V;
Haematologica; 2017 Jun; 102(6):1112-1119. PubMed ID: 28255019
[TBL] [Abstract][Full Text] [Related]
10. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.
Slavin S; Nagler A; Naparstek E; Kapelushnik Y; Aker M; Cividalli G; Varadi G; Kirschbaum M; Ackerstein A; Samuel S; Amar A; Brautbar C; Ben-Tal O; Eldor A; Or R
Blood; 1998 Feb; 91(3):756-63. PubMed ID: 9446633
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia.
Kang HJ; Shin HY; Choi HS; Ahn HS
Bone Marrow Transplant; 2004 Dec; 34(11):939-43. PubMed ID: 15489866
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody T-cell-depleted HLA-haploidentical bone marrow transplantation for Wiskott-Aldrich syndrome.
Rumelhart SL; Trigg ME; Horowitz SD; Hong R
Blood; 1990 Feb; 75(4):1031-5. PubMed ID: 2302455
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow transplantation for the Wiskott-Aldrich syndrome. Long-term follow-up.
Rimm IJ; Rappeport JM
Transplantation; 1990 Oct; 50(4):617-20. PubMed ID: 2219285
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Kato K; Yoshida N; Matsumoto K; Matsuyama T
Pediatr Blood Cancer; 2014 Apr; 61(4):712-6. PubMed ID: 24376191
[TBL] [Abstract][Full Text] [Related]
15. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow transplantation for the treatment of immune deficiency states.
Lenarsky C; Parkman R
Bone Marrow Transplant; 1990 Dec; 6(6):361-9. PubMed ID: 1965792
[TBL] [Abstract][Full Text] [Related]
17. [Platelet function after allogeneic bone marrow transplantation in Wiskott-Aldrich syndrome].
Megido M; Cesar JM; Maldonado MS; Otheo E; Muñoz A; Navarro JL
Sangre (Barc); 1993 Jun; 38(3):233-4. PubMed ID: 8211550
[TBL] [Abstract][Full Text] [Related]
18. Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
Modi D; Singh V; Kim S; Ayash L; Deol A; Ratanatharathorn V; Uberti JP
Ann Hematol; 2021 Apr; 100(4):969-978. PubMed ID: 33594448
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R
Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
